Neuroendokrine Tumoren

Forschungsthemen

Molekularpathologie der Schilddrüsenkarzinome

Hauptkooperationspartner: Prof. Dr. T. Musholt, Endokrine Chirurgie, Klinik für Allgemein-, Viszeral- und Transplantationschirurgie 

Gastrointestinale Tumore

Prädiktive Marker in der klinischen Onkologie

Hauptkooperationspartner: Prof. Dr. M. Möhler, gastroenterologisch-onkologische Ambulanz, I. Medizinische Klinik und Poliklinik

weitere Kooperationen:
Dr. S. Thaler, CBTM, Medizinische Fakultät Mannheim, onkologische Signaltransduktion; 

Ausgewählte Publikationen

• Watzka FM, Fottner C, Miederer M, Weber MM, Schad A, Lang H, Musholt TJ (2016)
  Surgical Treatment of NEN of Small Bowel: A Retrospective Analysis.
  World J Surg 40:749-58. doi: 10.1007/s00268-016-3432-2.
• Watzka FM, Fottner C, Miederer M, Schad A, Weber MM, Otto G, Lang H, Musholt TJ (2015)
  Surgical therapy of neuroendocrine neoplasm with hepatic metastasis: patient selection and prognosis.
  Langenbecks Arch Surg 400:349-58. doi: 10.1007/s00423-015-1277-z.
• Thaler S, Thiede G, Hengstler JG, Schad A, Schmidt M, Sleeman JP (2015)
  The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
  Int J Cancer 137:686-97. doi: 10.1002/ijc.29404.
• Thomaidis T, Maderer A, Formentini A, Bauer S, Trautmann M, Schwarz M, Neumann W, Kittner J, Schad A, Link KH, Rey J, Weinmann A, Hoffman A, Galle P, Kornmann M, Moehler M (2014)
  Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial.
  J Exp Clin Cancer Res 33:83 [Epub ahead of print]
• Thomaidis T, Maderer A, Al-Batran SE, Kany J, Pauligk C, Steinmetz K, Schad A, Hofheinz R, Schmalenberg H, Homann N, Galle PR, Moehler M (2014)
  VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
  BMC Cancer 14:476 doi: 10.1186/1471-2407-14-476.
• Bickmann JK, Sollfrank S, Schad A, Musholt TJ, Springer E, Miederer M, Bartsch O, Papaspyrou K, Koutsimpelas D, Mann WJ, Weber MM, Lackner KJ, Rossmann H, Fottner C (2014)
  Phenotypic variability and risk of malignancy in SDHC-linked paragangliomas: Lessons from 3 unrelated cases with an identical germline mutation (p.Arg133*).
  J Clin Endocrinol Metab. 2014 Jan 1:jc20133486.
• Oue N, Anami K, Schetter AJ, Moehler M, Okayama H, Khan MA, Bowman ED, Mueller A, Schad A, Shimomura M, Hinoi T, Aoyagi K, Sasaki H, Okajima M, Ohdan H, Galle PR, Yasui W, Harris CC (2014)
  High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer.
  Int J Cancer 134:1926–1934
• Watzka FM, Laumen C, Fottner C, Weber MM, Schad A, Lang H, Musholt TJ (2012)
  Resection strategies for neuroendocrine pancreatic neoplasms.
  Langenbecks Arch Surg doi: 10.1007/s00423-012-1024-7
• Thaler S, Schmidt M, Schad A, Sleeman JP (2012)
  RASSF1A inhibits estrogen receptor alpha expression and estrogen-independent signalling: implications for breast cancer development.
  Oncogene 31:4912–4922
• Musholt TJ, Fottner C, Weber MM, Eichhorn W, Pohlenz J, Musholt PB, Springer E, Schad A (2010)
  Detection of Papillary Thyroid Carcinoma by Analysis of BRAF and RET/PTC1 Mutations in Fine-needle Aspiration Biopsies of Thyroid Nodules.
  World J Surg 34:2595–2603
• Musholt TJ, Schönefeld S, Schwarz CH, Watzka FM, Musholt PB, Fottner C, Weber MM, Springer E, Schad A (2010)
  Impact of pathognomonic genetic alterations on the prognosis of papillary thyroid carcinoma : ESES vienna presentation.
  Langenbecks Arch Surg 395:877–883
• García-Caballero T, Grabau D, Green AR, Gregory J, Schad A, Kohlwes E, Ellis IO, Watts S, Mollerup J (2010)
  Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens.
  Histopathology 56:472–480
• Borschitz T, Eichhorn W, Fottner C, Hansen T, Schad A, Schadmand-Fischer S, Weber MM, Schreckenberger M, Lang H, Musholt TJ (2010)
  Diagnosis and treatment of pancreatic metastases of a papillary thyroid carcinoma.
  Thyroid 20:93–98
• Foltys D, Linkermann A, Heumann A, Hoppe-Lotichius M, Heise M, Schad A, Schneider J, Bender K, Schmid M, Mauer D, Peixoto N, Otto G (2009)
  Organ recipients suffering from undifferentiated neuroendocrine small-cell carcinoma of donor origin: a case report.
  Transplant Proc 41:2639–2642
• Thaler S, Hähnel PS, Schad A, Dammann R, Schuler M (2009)
  RASSF1A mediates p21Cip1/Waf1-dependent cell cycle arrest and senescence through modulation of the Raf-MEK-ERK pathway and inhibition of Akt.
  Cancer Res 69:1748–1757
• Schulze-Bergkamen H, Ehrenberg R, Hickmann L, Vick B, Urbanik T, Schimanski CC, Berger MR, Schad A, Weber A, Heeger S, Galle PR, Moehler M (2008)
  Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells.
  World J Gastroenterol 14:3829–3840

AG-Mitarbeiter

Dr. med. Arno Schad

Dr. med.  Kristina Krümpelmann

Fr. Heike Zimmer-Zachmann

Kontaktadresse

Dr. med. Arno Schad